A game changing year for Oxford BioMedica?
Gene therapy company Oxford BioMedica (OXB) could be on the cusp of receiving a lucrative flow of money over many years, potentially worth up to $65m to $75m annually in the medium term.Novartis is expected to submit its CTL019...
02 March 2017